CytoGenix Announces Drs. Stein and Chen Report Cancer Breakthrough to Gene Therapy Conferees.

Business Editors & Health/Medical Writers

HOUSTON--(BUSINESS WIRE)--Dec. 17, 2001

CytoGenix Inc.(OTCBB:CYGX) Scientific Advisory Board member, Dr. Cy Stein and Dr. Yin Chen, company R&D VP, presented the results of research using CYGX' single stranded DNA expression system at the Gene Therapy of Cancer Conference at San Diego. Dr. Stein's research was conducted at Columbia University School of Medicine under a Sponsored Research Agreement with CYGX. Dr. Stein announced his laboratory's achievement of a 95% knock out of the target protein, PKC-Alpha, considered to be essential to the survival and proliferation of prostate and bladder cancer. Dr. Stein is an associate professor of pharmacology and clinical medicine in the Departments of Medicine and Pharmacology at Columbia University, College of Physicians and Surgeons, and a senior staff fellow at the National Cancer Institute at Bethesda, Md.

Leading researchers from around the world presented the latest results of their pre-clinical and clinical studies of cancer treatment using gene therapy technology to the Tenth International Gene Therapy of Cancer Conference. The program included sessions focusing on treatment resistance and sensitivity gene therapy, tumor suppressors, oncogenes, apoptosis genes, immunogene therapy and antisense therapy.

Dr. Stein chaired the opening session of the Gene Therapy Conference, covering the subjects of Tumor Suppressors, Apoptosis and Antisense-Ribozomes. He also made the first presentation entitled, "Molecular Consequences of Antisense DNA and RNA Knockout of Bcl-2 and Bclxl."

Later in the session, Dr. Chen, one of the inventors of the CYGX ssDNA expression system used by Dr. Stein, presented, "Novel Intracellular Single-Stranded DNA Expression System: Production of c-raf RNA-Cleaving DNA Enzyme." During his presentation, Dr. Chen provided further details of the unprecedented 95% knock out of Dr. Stein's target protein along with the results of his own experiments on c-raf suppression. Dr. Chen compared both these results with results produced by Dr. Peter Glazer's laboratory at Yale University. Dr. Glazer's results will be published in Nucleic Acids Research on or about Dec. 15, 2001, in a paper entitled, "Intracellular generation of single-stranded DNA for chromosomal triplex formation and induced recombination," co-authored by Dr. Hirock J. Datta. Dr. Glazer is an associate professor of therapeutic radiology and genetics in the Medical School at Yale University. Dr. Glazer is also a member of the CYGX scientific advisory board.

Dr. Malcolm Skolnick, CYGX president and CEO, notes that Dr. Chen's use of ssDNA as a DNA enzyme, Dr. Stein's antisense application, and Dr. Glazer's use of the ssDNA expression system to achieve triplex formation show the breadth of applications and the efficiency of the CYGX ssDNA expression systems.

CytoGenix Inc. is a Houston-based genomics research and development company with proprietary technology important in the advancement of various Oligonucleotide-Mediated Intervention (OMI) therapies. OMI therapies are those that impede the production of disease causing proteins at their genetic origins through the introduction of specific single stranded DNA (ODN) sequences into the cells.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition and other factors more fully detailed in the company's filings with the Securities and Exchange Commission.

Additional information about CytoGenix and its technology can be found on the Web site at www.cytogenix.com or call Dell Gibson at 281/988-6118, Investor Relations/Corporate Communications.